I recommended a buy rating for Health Catalyst (NASDAQ: HCAT ) when I wrote about it in March, as I was confident that HCAT could achieve its FY28 targets by executing growth strategies that have a stronger I consider an investment ideal if it performs its core business in a sector projected to experience structural (organic) growth in excess of GDP growth over the next 5-10 years; profits from sustainable competitive advantages that translate into attractive unit economics; In the hands of competent, ethic ...

SALT LAKE CITY, Aug. 27, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Wisconsin Statewide Health Information Network, Inc. (WISHIN), an independent not-for-profit organization dedicated to bringing the benefits of widespread, secure, interoperable health information technology to patients and caregivers throughout Wisconsin, has selected to expand its multi-year ...

Core Insights - Health Catalyst has successfully completed the acquisition of Lumeon Limited, a digital health company focused on automated care orchestration [1][2] - The acquisition aims to enhance Health Catalyst's data analytics capabilities and improve clinical care through Lumeon's technology [2][4] - Health Catalyst expects to leverage Lumeon's presence in the UK to expand into new international markets [3] Company Overview - Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations, utilizing a cloud-based platform powered by over 100 million patient records [5] - The company is committed to enabling data-informed healthcare improvements and enhancing clinical, financial, and operational outcomes for its clients [5] Strategic Goals - The integration of Lumeon's Care Orchestration technology with Health Catalyst's Ignite AI platform is expected to provide healthcare organizations with data-driven insights and automate clinical actions [4] - This acquisition is anticipated to strengthen Health Catalyst's focus on clinical improvement and support its Tech-Enabled Managed Services partnerships [2][4]

SALT LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced an expanded partnership with Contexture, a nonprofit, regional health information exchange organization that works to drive health data interoperability. Contexture supports the flow of health information between thousands of physician practices, hospitals, long-term care facilities, labs, radiology ...

Health Catalyst (HCAT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this provider of data analytics for the health care industry would post earnings of $0.03 per share when it actually produced earnings of $0.05, delivering a surprise of ...

"This financing is an important milestone for Health Catalyst and its shareholders. The Credit Facility not only assists with refinancing our existing convertible notes, but also provides flexibility and additional non-dilutive capital for us to continue to proactively pursue meaningful organic and inorganic growth opportunities, and to continue to act as a consolidation platform for our clients, integrating compelling technologies within our five areas of focus, which we believe positions us well to create ...

Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. A Dana-Farber Cancer Institute study also indicated that telemedicine may considerably cut cancer treatment greenhouse gas emissions. Under these circumstances, telehealth stocks will only gain favor with the investing community. That's why we'll explore three undervalued telehealth stocks, each wit ...

Core Insights - Health Catalyst has successfully acquired Carevive Systems, enhancing its capabilities in oncology-focused health technology [1][2] - The acquisition aims to improve patient care and outcomes in oncology through better data and analytics [3][4] Company Overview - Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations, leveraging a cloud-based data platform with over 100 million patient records [5] - Carevive Systems specializes in oncology, focusing on improving the patient experience and providing data for treatment planning and clinical trials [2][4] Strategic Importance - The acquisition is seen as a pivotal moment for both companies, emphasizing the importance of high-quality data in oncology care [3][4] - The partnership aims to amplify the patient's voice in cancer care and enhance the delivery of innovative solutions to cancer centers [4]

Core Insights - Health Catalyst, Inc. is actively participating in upcoming investor conferences, indicating a focus on investor engagement and communication [1] - The company is a leading provider of data and analytics technology and services specifically tailored for healthcare organizations [2] Company Overview - Health Catalyst aims to drive significant, measurable improvements in healthcare through data-informed decision-making [2] - The company utilizes a cloud-based data platform that integrates data from over 100 million patient records, encompassing trillions of facts [2] - Health Catalyst's offerings include analytics software and professional services to help clients achieve clinical, financial, and operational enhancements [2] Upcoming Events - Jason Alger, CFO, and Jack Knight, VP of Investor Relations, will participate in the Stifel Cross Sector Insight Conference on June 4, 2024, at 9:45am ET [1] - The company will also present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:40am ET [1]

Investors might want to bet on Health Catalyst (HCAT) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. 12 Month EPS Current-Quarter Estimate Revisions The earnings estimate of $0.09 per share for the current quarter represents a change of +80% from the number reported a year ago. The Zacks Consensus Estimate for Health Catalyst has increas ...